• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LBT
Click for more information
5.00% 1.9¢

LBT INNOVATIONS LIMITED - Announcements

Market Cap $23.13M  ! watchlist Created with Sketch. Add to my watchlist

LBT Innovations Limited is a medical technology company. The Company is engaged in... LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.More

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
LBT Appendix 4G25/09/15
LBT Annual Report to shareholders25/09/15
LBT Notice of Annual General Meeting/Proxy Form18/09/15
LBT Resubmission of 3Y - 17 September 201518/09/15
LBT Change of Director's Interest Notice18/09/15
LBT Change of Director's Interest Notice17/09/15
LBT Change of Director's Interest Notice04/09/15
LBT Change of Director's Interest Notice01/09/15
LBT LBT Innovations Market UpdatePRICE SENSITIVE28/08/15
LBT Preliminary Final ReportPRICE SENSITIVE27/08/15
LBT LBT Signs Agreement with bioMerieuxPRICE SENSITIVE27/08/15
LBT Change in substantial holding31/07/15
LBT Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
LBT Change in substantial holding30/07/15
LBT LBT begins key U.S. trial of APAS technologyPRICE SENSITIVE09/06/15
LBT Appendix 4C - quarterlyPRICE SENSITIVE28/04/15
LBT Shareholder News - April 201530/03/15
LBT LBT Granted First U.S. Patent for APAS TechnologyPRICE SENSITIVE26/03/15
LBT Appendix 4DPRICE SENSITIVE27/02/15
LBT Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
LBT Notice of Intent re PREVI Isola Licence AgreementPRICE SENSITIVE12/01/15
LBT CEO Presentation at Ausbiotech Biotech Invest Summit03/12/14
LBT LBT Completes Australian Clinical Trials of APAS TechnologyPRICE SENSITIVE26/11/14
LBT Change of Company Secretary20/11/14
LBT Results of Meeting28/10/14
LBT AGM CEO Presentation28/10/14
LBT Chairman's Address to Shareholders28/10/14
LBT Appendix 4C - quarterlyPRICE SENSITIVE24/10/14
LBT LBT Awarded $250,000 Grant for WoundvuePRICE SENSITIVE20/10/14
LBT Change of Director's Interest Notice13/10/14
LBT Notice of Annual General Meeting/Proxy Form19/09/14
LBT Annual Report to shareholders19/09/14
LBT LBT Begins Clinical Trials of APAS TechnologyPRICE SENSITIVE19/09/14
LBT LBT Innovations receives $3M 2014 R&D tax incentivePRICE SENSITIVE04/09/14
LBT Appendix 4EPRICE SENSITIVE29/08/14
LBT LBT Innovations Appoints Chief Financial Officer28/08/14
LBT LBT APPOINTS US-BASED CLINICAL TRIAL CO-ORDINATOR25/08/14
LBT Despatch of SPP and Tranche 2 Holding Statements13/08/14
LBT Notice of initial substantial holder12/08/14
LBT Placement - Cleansing Notice07/08/14
LBT Change of Director's Interest Notice07/08/14
LBT Change of Director's Interest Notice07/08/14
LBT Change of Director's Interest Notice07/08/14
LBT Appendix 3B07/08/14
LBT Change of Director's Interest Notice07/08/14
LBT Appendix 3B07/08/14
LBT Office Relocation06/08/14
LBT Results of EGM01/08/14
LBT Chairman's Address to Shareholders01/08/14
LBT Appendix 4C - quarterly reportPRICE SENSITIVE31/07/14
LBT Completion of Share Purchase Plan Raising25/07/14
LBT LBT Innovations Presents Results of Most Extensive Study07/07/14
LBT Despatch of Share Purchase Plan Offer Documents27/06/14
LBT Placement - Tranche 1 Cleansing Notice25/06/14
LBT Appendix 3B25/06/14
LBT LBT raises A$1.5M in private placementPRICE SENSITIVE18/06/14
LBT Trading HaltPRICE SENSITIVE16/06/14
LBT LBT Innovations receives third $1M milestone paymentPRICE SENSITIVE11/06/14
LBTUpdated Investor and Shareholder Presentation13/05/14
LBTInvestor and Shareholder Presentation12/05/14
LBTLBT Innovations Introduces Landmark Diagnostic PlatformPRICE SENSITIVE12/05/14
LBTAppendix 4C - quarterlyPRICE SENSITIVE28/04/14
LBTResponse to Price QueryPRICE SENSITIVE10/04/14
LBTChange of Director's Interest Notice18/03/14
LBTChange of Director's Interest Notice11/03/14
LBTAppendix 4D Half Year ResultsPRICE SENSITIVE20/02/14
LBTAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
LBTAppendix 3B11/12/13
LBTAppendix 3B09/12/13
LBTChange of Director's Interest Notice05/12/13
LBTResults of Meeting26/11/13
LBTAGM CEO Presentation26/11/13
LBTChairman's Address to Shareholders26/11/13
LBTNotice of Annual General Meeting/Proxy Form22/10/13
LBTAppendix 4C - quarterlyPRICE SENSITIVE17/10/13
LBTAnnual Report to shareholders27/09/13
LBTPreliminary Final ReportPRICE SENSITIVE21/08/13
LBTAppendix 4C - quarterlyPRICE SENSITIVE26/07/13
LBTLBT wins grant for APAS developmentPRICE SENSITIVE03/07/13
LBTProfit GuidancePRICE SENSITIVE02/07/13
LBTChange of Director's Interest Notice01/07/13
LBTChange of Director's Interest Notice01/07/13
LBTOptions Expiry Notice01/07/13
LBTLBT Innovations Finalises Joint VenturePRICE SENSITIVE25/06/13
LBTTrading HaltPRICE SENSITIVE21/06/13
LBTMarket update on discussions with Hettich AG Switzerland17/06/13
LBTOptions Expiry Notice28/05/13
LBTMarket update on discussions with Hettich AG Switzerland15/05/13
LBTAppendix 4C - quarterlyPRICE SENSITIVE17/04/13
LBTLBT enters into exclusive discussionsPRICE SENSITIVE15/04/13
LBTAppendix 4D Half Year ResultsPRICE SENSITIVE27/02/13
LBTAppendix 4C - quarterlyPRICE SENSITIVE25/01/13
LBTEarnings GuidancePRICE SENSITIVE14/12/12
LBTExpiry of Options05/12/12
LBTChange of Director's Interest Notice29/11/12
LBTAppendix 3B29/11/12
LBTResults of Meeting20/11/12
LBTAGM 2012 Director's Presentation C. Popper20/11/12
LBTAGM 2012 CEO/MD's Address20/11/12
LBTChairman's Address to Shareholders20/11/12
LBT Appendix 4G
25/09/15
LBT Annual Report to shareholders
25/09/15
LBT Notice of Annual General Meeting/Proxy Form
18/09/15
LBT Resubmission of 3Y - 17 September 2015
18/09/15
LBT Change of Director's Interest Notice
18/09/15
LBT Change of Director's Interest Notice
17/09/15
LBT Change of Director's Interest Notice
04/09/15
LBT Change of Director's Interest Notice
01/09/15
LBT LBT Innovations Market Update
28/08/15PRICE SENSITIVE
LBT Preliminary Final Report
27/08/15PRICE SENSITIVE
LBT LBT Signs Agreement with bioMerieux
27/08/15PRICE SENSITIVE
LBT Change in substantial holding
31/07/15
LBT Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
LBT Change in substantial holding
30/07/15
LBT LBT begins key U.S. trial of APAS technology
09/06/15PRICE SENSITIVE
LBT Appendix 4C - quarterly
28/04/15PRICE SENSITIVE
LBT Shareholder News - April 2015
30/03/15
LBT LBT Granted First U.S. Patent for APAS Technology
26/03/15PRICE SENSITIVE
LBT Appendix 4D
27/02/15PRICE SENSITIVE
LBT Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
LBT Notice of Intent re PREVI Isola Licence Agreement
12/01/15PRICE SENSITIVE
LBT CEO Presentation at Ausbiotech Biotech Invest Summit
03/12/14
LBT LBT Completes Australian Clinical Trials of APAS Technology
26/11/14PRICE SENSITIVE
LBT Change of Company Secretary
20/11/14
LBT Results of Meeting
28/10/14
LBT AGM CEO Presentation
28/10/14
LBT Chairman's Address to Shareholders
28/10/14
LBT Appendix 4C - quarterly
24/10/14PRICE SENSITIVE
LBT LBT Awarded $250,000 Grant for Woundvue
20/10/14PRICE SENSITIVE
LBT Change of Director's Interest Notice
13/10/14
LBT Notice of Annual General Meeting/Proxy Form
19/09/14
LBT Annual Report to shareholders
19/09/14
LBT LBT Begins Clinical Trials of APAS Technology
19/09/14PRICE SENSITIVE
LBT LBT Innovations receives $3M 2014 R&D tax incentive
04/09/14PRICE SENSITIVE
LBT Appendix 4E
29/08/14PRICE SENSITIVE
LBT LBT Innovations Appoints Chief Financial Officer
28/08/14
LBT LBT APPOINTS US-BASED CLINICAL TRIAL CO-ORDINATOR
25/08/14
LBT Despatch of SPP and Tranche 2 Holding Statements
13/08/14
LBT Notice of initial substantial holder
12/08/14
LBT Placement - Cleansing Notice
07/08/14
LBT Change of Director's Interest Notice
07/08/14
LBT Change of Director's Interest Notice
07/08/14
LBT Change of Director's Interest Notice
07/08/14
LBT Appendix 3B
07/08/14
LBT Change of Director's Interest Notice
07/08/14
LBT Appendix 3B
07/08/14
LBT Office Relocation
06/08/14
LBT Results of EGM
01/08/14
LBT Chairman's Address to Shareholders
01/08/14
LBT Appendix 4C - quarterly report
31/07/14PRICE SENSITIVE
LBT Completion of Share Purchase Plan Raising
25/07/14
LBT LBT Innovations Presents Results of Most Extensive Study
07/07/14
LBT Despatch of Share Purchase Plan Offer Documents
27/06/14
LBT Placement - Tranche 1 Cleansing Notice
25/06/14
LBT Appendix 3B
25/06/14
LBT LBT raises A$1.5M in private placement
18/06/14PRICE SENSITIVE
LBT Trading Halt
16/06/14PRICE SENSITIVE
LBT LBT Innovations receives third $1M milestone payment
11/06/14PRICE SENSITIVE
LBTUpdated Investor and Shareholder Presentation
13/05/14
LBTInvestor and Shareholder Presentation
12/05/14
LBTLBT Innovations Introduces Landmark Diagnostic Platform
12/05/14PRICE SENSITIVE
LBTAppendix 4C - quarterly
28/04/14PRICE SENSITIVE
LBTResponse to Price Query
10/04/14PRICE SENSITIVE
LBTChange of Director's Interest Notice
18/03/14
LBTChange of Director's Interest Notice
11/03/14
LBTAppendix 4D Half Year Results
20/02/14PRICE SENSITIVE
LBTAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
LBTAppendix 3B
11/12/13
LBTAppendix 3B
09/12/13
LBTChange of Director's Interest Notice
05/12/13
LBTResults of Meeting
26/11/13
LBTAGM CEO Presentation
26/11/13
LBTChairman's Address to Shareholders
26/11/13
LBTNotice of Annual General Meeting/Proxy Form
22/10/13
LBTAppendix 4C - quarterly
17/10/13PRICE SENSITIVE
LBTAnnual Report to shareholders
27/09/13
LBTPreliminary Final Report
21/08/13PRICE SENSITIVE
LBTAppendix 4C - quarterly
26/07/13PRICE SENSITIVE
LBTLBT wins grant for APAS development
03/07/13PRICE SENSITIVE
LBTProfit Guidance
02/07/13PRICE SENSITIVE
LBTChange of Director's Interest Notice
01/07/13
LBTChange of Director's Interest Notice
01/07/13
LBTOptions Expiry Notice
01/07/13
LBTLBT Innovations Finalises Joint Venture
25/06/13PRICE SENSITIVE
LBTTrading Halt
21/06/13PRICE SENSITIVE
LBTMarket update on discussions with Hettich AG Switzerland
17/06/13
LBTOptions Expiry Notice
28/05/13
LBTMarket update on discussions with Hettich AG Switzerland
15/05/13
LBTAppendix 4C - quarterly
17/04/13PRICE SENSITIVE
LBTLBT enters into exclusive discussions
15/04/13PRICE SENSITIVE
LBTAppendix 4D Half Year Results
27/02/13PRICE SENSITIVE
LBTAppendix 4C - quarterly
25/01/13PRICE SENSITIVE
LBTEarnings Guidance
14/12/12PRICE SENSITIVE
LBTExpiry of Options
05/12/12
LBTChange of Director's Interest Notice
29/11/12
LBTAppendix 3B
29/11/12
LBTResults of Meeting
20/11/12
LBTAGM 2012 Director's Presentation C. Popper
20/11/12
LBTAGM 2012 CEO/MD's Address
20/11/12
LBTChairman's Address to Shareholders
20/11/12
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
1.9¢ 		Change
-0.001(5.00%) 		Mkt cap ! $23.13M
Open High Low Value Volume
1.9¢ 1.9¢ 1.9¢ $4.463K 234.8K

Buyers (Bids)

No. Vol. Price($)
3 950618 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 278267 1
View Market Depth
Last trade - 13.53pm 22/11/2024 (20 minute delay) ?
Last
1.8¢ 		  Change
-0.001 ( 5.26 %)
Open High Low Volume
1.9¢ 1.9¢ 1.8¢ 153983
Last updated 14.57pm 22/11/2024 ?
LBT (ASX) Chart

Top Stories

Sales growth pushes Lovisa's fortunes (and shares) upwards

Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.